Outset Medical, Inc. (NASDAQ:OM – Get Free Report) General Counsel John L. Brottem sold 20,492 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $0.81, for a total transaction of $16,598.52. Following the completion of the sale, the general counsel now directly owns 205,028 shares in the company, valued at $166,072.68. This trade represents a 9.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Outset Medical Price Performance
Outset Medical stock opened at $0.81 on Wednesday. The stock has a market capitalization of $42.67 million, a P/E ratio of -0.29 and a beta of 2.05. Outset Medical, Inc. has a 12-month low of $0.44 and a 12-month high of $5.22. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.49 and a quick ratio of 5.04. The firm’s 50-day moving average is $1.01 and its two-hundred day moving average is $1.39.
Analysts Set New Price Targets
Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $3.00 target price on shares of Outset Medical in a research note on Tuesday, January 7th.
Institutional Trading of Outset Medical
Hedge funds have recently bought and sold shares of the company. Massachusetts Financial Services Co. MA grew its holdings in Outset Medical by 118.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,538,859 shares of the company’s stock valued at $5,925,000 after buying an additional 834,663 shares during the period. Vanguard Personalized Indexing Management LLC purchased a new stake in Outset Medical in the second quarter valued at approximately $49,000. Marshall Wace LLP increased its position in Outset Medical by 487.8% during the second quarter. Marshall Wace LLP now owns 314,187 shares of the company’s stock worth $1,210,000 after purchasing an additional 260,740 shares during the last quarter. Cubist Systematic Strategies LLC raised its stake in Outset Medical by 228.3% during the second quarter. Cubist Systematic Strategies LLC now owns 200,939 shares of the company’s stock worth $774,000 after purchasing an additional 139,740 shares during the period. Finally, Squarepoint Ops LLC boosted its holdings in shares of Outset Medical by 74.1% in the 2nd quarter. Squarepoint Ops LLC now owns 80,300 shares of the company’s stock valued at $309,000 after purchasing an additional 34,187 shares during the last quarter.
Outset Medical Company Profile
Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
See Also
- Five stocks we like better than Outset Medical
- Best Stocks Under $5.00
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- How to Most Effectively Use the MarketBeat Earnings Screener
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.